MedTrace Logo

Clinical Evaluation of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke

NCT04200781 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 464

Last updated 2019-12-16

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke by the randomized, controlled, double-blind, multi-center trial design project.

Conditions

  • Hemorrhagic Stroke

Interventions

DRUG

Granules of Shengdi Dahuang Decoction

Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.

DRUG

Placebo

Placebo granules has the same appearence, weight, shape and color as the experimental drug.

Sponsors & Collaborators

  • ShuGuang Hospital

    lead OTHER

Principal Investigators

  • Xiaofei Yu · Shuguang Hospital affiliated with Shanghai University of TCM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04200781 on ClinicalTrials.gov